Precision BioSciences, Inc. (NASDAQ:DTIL) Shares Sold by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC lessened its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 35.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,699 shares of the company’s stock after selling 17,500 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in Precision BioSciences were worth $284,000 at the end of the most recent quarter.

Separately, Janus Henderson Group PLC purchased a new position in shares of Precision BioSciences during the 1st quarter worth $7,739,000. Institutional investors own 37.99% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Precision BioSciences in a report on Thursday, August 22nd.

Precision BioSciences Trading Down 0.7 %

Shares of DTIL opened at $8.40 on Thursday. The firm has a market cap of $60.77 million, a P/E ratio of 140.00 and a beta of 1.71. Precision BioSciences, Inc. has a 12-month low of $7.97 and a 12-month high of $19.43. The company’s 50-day moving average price is $9.31 and its 200 day moving average price is $10.05.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.